Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A01012 | Pages: 197 | Charts: 63 | Tables: 68 |
Asia-Pacific Anti-inflammatory Therapeutics Market Statistics 2030:
The Asia-Pacific anti-inflammatory therapeutics market size was valued at $23.8 Billion in 2022, and is projected to reach $40.5 Billion by 2032, registering a CAGR of 5.4% from 2023 to 2032. Anti-inflammatory therapeutics are a group of drugs designed to reduce inflammation, a protective response by the body to injury or pathogens. These drugs act primarily by inhibiting pathways and molecules responsible for the inflammatory response. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) work by blocking enzymes (COX-1 and COX-2) involved in prostaglandin synthesis that mediate inflammation. While NSAIDs and corticosteroids are the primary treatment option for inflammation, biologics are the newer class of medicines known to be effective in treating chronic inflammation.
However, there is still no cure for many chronic, autoimmune and respiratory inflammatory diseases. It highlights the impending need for effective and innovative anti-inflammatory medicines. Anti-inflammatory therapeutics are widely used to manage inflammatory conditions such as arthritis, psoriasis, multiple sclerosis, asthma, and others.
Market Dynamics
The Asia-Pacific anti-inflammatory therapeutics market growth is driven by increase in R&D activities for novel medication development, rise in prevalence of inflammatory diseases, such as psoriasis, arthritis, and respiratory diseases, and increase in approvals of new anti-inflammatory drugs. Through extensive research, scientists can identify potential drug targets, and conduct preclinical and clinical trials to test the safety and efficacy of new drugs. Such innovation leads to the creation of new anti-inflammatory drugs, which address unmet medical needs, improve treatment outcomes, and enhance patient care.
In addition, pharmaceutical companies invest in post-approval R&D activities to expand the therapeutic applications of anti-inflammatory therapeutics and develop new formulations or explore combination therapies. These strategies aim to enhance the clinical benefits of existing drugs and further drives the market growth. In addition, many pharmaceutical companies invest heavily in R&D, which is projected to boost the market growth. For instance, Sanofi S.A. has more than 10 products in the phase-1 and phase-2 evaluation for the treatment of asthma, psoriasis, ulcerative colitis, and others.
Further, Takeda Pharmaceuticals, a global leader in pharmaceuticals industry, has TAK-279 drugs for the treatment of psoriatic arthritis in the phase 2 evaluation. Thus, strong product pipeline is the key factor which is expected to create lucrative opportunities for the market growth during the forecast period.
In addition, the increase in product approvals by regulatory authorities also drives the growth of the Asia-Pacific anti-inflammatory therapeutics market. Approved drugs are marketed and sold to healthcare providers, which expand their accessibility to patients. This market expansion leads to increased revenue generation which, in turn, supports the growth of the Asia-Pacific anti-inflammatory therapeutics market. For instance, in May 2021, AbbVie Inc. a global pharmaceutical company receives approval for the additional indication of RINVOQ tablets for psoriatic arthritis in Japan. Therefore, such product approvals are expected to drive the growth of the Asia-Pacific anti-inflammatory therapeutics market during the forecast period.
Furthermore, availability of biologic drugs for the treatment of inflammatory conditions with potent mechanism of action also contribute towards the market growth. For instance, SKYRIZI is a biologic drug commercialized by AbbVie Inc., and is widely used for the treatment of rheumatoid arthritis.
Increase in the prevalence of inflammatory diseases such as arthritis, inflammatory bowel disease, and others also supports the market growth. For instance, according to National Center for Biotechnology Information (NCBI), 2020, the prevalence of inflammatory bowel diseases is increasing in the Japan.
However, various side effects associated with corticosteroids and NSAIDs restrain the growth of the Asia-Pacific anti-inflammatory therapeutics market. NSAIDs, can lead to gastrointestinal issues such as ulcers, bleeding, or perforation. In addition, they also increase the risk of heart attack and stroke. On the other hand, long term use of corticosteroids can lead to osteoporosis. Thus, side-effects associated with inflammatory drugs hampers the market growth.
On the other hand, new product approvals and product launches are expected to create new opportunities for market growth during the forecast period. These product approvals will expand the treatment options for various inflammatory diseases such as arthritis, psoriasis and others.
The Asia-Pacific region's pharmaceutical and biotechnology sectors are somewhat affected by the continuing economic recession. The demand for pharmaceuticals, including anti-inflammatory therapies, has fluctuated as a result of decreased investment in industries such as pharmaceuticals and biotechnology. In addition, patients may skip routine check-ups for gastrointestinal problems and other disorders during a recession due to the economic downturn. This may lead to lower prescription rates and a decline in the demand for drugs. Thus, recession has a moderate impact on the Asia-Pacific anti-inflammatory therapeutics market.
Segmental Overview
The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of drug class, indication, distribution channel, and region. On the basis of drug class, the market is segmented into biologics, NSAIDs, corticosteroids, and others. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, and inflammatory bowel disease, and others. By distribution channel, it is divided into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Country wise, the market is analyzed across Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific.
By Drug Class
The Asia-Pacific anti-inflammatory therapeutics market is segmented into biologics, NSAIDs, corticosteroids, and others. The biologics segment dominated the global market in 2022 and is expected to remain dominant throughout the forecast period. This is attributed to increase in new product approvals for biologics in Japan and other countries. Furthermore, biologics have higher efficacy and fewer off-target effects which makes them highly effective to treat inflammatory diseases. In addition, biologics are widely applicable in the treatment of various inflammatory conditions such as arthritis, ankylosing spondylitis, psoriasis, multiple sclerosis, and also contribute towards the growth of the segment. Further, biologics are widely preferred due to its specific action and fewer side effects than other anti-inflammatory drugs such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).
[DRUGCLASSGRAPH]
By Indication
The Asia-Pacific anti-inflammatory therapeutics market is segregated into arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease, and others. The arthritis segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to an increase in prevalence of rheumatoid arthritis and increase in number of people taking treatment for rheumatoid arthritis. Furthermore, launch of new biologic drugs for the treatment of arthritis also contribute towards the segment growth. Biologics are the drugs that effectively treat the arthritis thereby contributing towards the market growth.
[INDICATIONGRAPH]
By Distribution Channel
The Asia-Pacific anti-inflammatory therapeutics market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The drug stores & retail pharmacies segment dominated the global market in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to the increase in hospitalization rate and surge in demand for anti-inflammatory therapeutics through retail pharmacies and drug stores. In addition, easy availability of over the counter NSAIDs also contribute towards the revenue generated by drug stores and retail pharmacies. Further, increase in the number of people taking treatments for the inflammatory diseases also boosts the growth of the market.
By Country
The Asia-Pacific anti-inflammatory therapeutics market is analyzed across Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific.
The presence of several major players, such as Pfizer Inc., Novartis AG, F. Hoffmann La-Roche Ltd., and Amgen Inc. and the rise in prevalence of various inflammatory conditions in the region drives the growth of the market. For instance, according to Narayana Health Organization the estimated prevalence of rheumatoid arthritis is 1% of the population in India. Increase in prevalence of rheumatoid arthritis leads to greater demand for ant-inflammatory drugs which drives the market growth. Moreover, easy accessibility and availability of anti-inflammatory therapeutics boost the growth of the market in this region.
Asia-Pacific region has a large population, and there has been an observed increase in the prevalence of cancer in recent years due to ageing population, lifestyle changes, and environmental factors. This has led to an increase in the number of patients suffering from cancer induced inflammatory conditions, which in turn increases the demand for anti-inflammatory therapeutics. For instance, in 2020, National Institute of Cancer Prevention and Research (NICPR), estimated that about 2.7 million people in India are living with cancer. In addition, growing adoption of anti-inflammatory therapeutics further propels the market growth. Moreover, development of pharmaceutical industry and increase in R&D activities boost the market growth in this region.
China is the largest growing country in Asia-Pacific region owing to, high population of diseased patients. On the other hand, Japan, is expected to be the fastest growing country during the forecast period. This is attributed to an increase in new product launches and product approvals in this country for inflammatory disease treatment.
Competition Analysis
Competitive analysis and profiles of the major players in the Asia-Pacific anti-inflammatory therapeutics market, include Abbvie Inc., Amgen Inc., Pfizer Inc., GalaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Novartis AG, Eli Lilly and Company, Bayer AG, and AstraZeneca plc. Major players have adopted product approval and product launch as key developmental strategies to improve the product portfolio and gain strong foothold in the Asia-Pacific anti-inflammatory therapeutics industry.
Recent Product Approvals in the Asia-Pacific Anti-inflammatory Therapeutics Market
In February 2023, AbbVie Inc., a global pharmaceutical company received additional indication approval in Japan for RINVOQ tablets (upadacitinib hydrate) for the treatment of adult patients with axial spondyloarthritis who do not meet x-ray criteria. Such product launches will help the company to further expand its anti-inflammatory therapeutics portfolio.
Recent Product Launches in the Asia-Pacific anti-inflammatory therapeutics Market
In February 2023, AbbVie Inc. launched 360mg subcutaneous injection auto doser, new formulation of SKYRIZI in Japan.
In January 2023, AbbVie Inc., a global leader in pharmaceutical industry launches new SKYRIZI intravenous infusion 600mg formulation in Japan. Such product launches will help to expand the product portfolio of the company.
In November 2021, AbbVie Inc., a global pharmaceutical company launched new 45mg tablet formulation of RINVOQ in Japan. The launch of RINVOQ will help the company to gain a strong foothold in the anti-inflammatory therapeutics market.
Key Benefits for Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits for stakeholders
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitution
3.3.4. Threat of new entrants
3.3.5. Intensity of competitive rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in prevalence of inflammatory diseases
3.4.1.2. Strong availability of biologic drugs
3.4.2. Restraint
3.4.2.1. Side-effects associated with anti-inflammatory drugs
3.4.3. Opportunity
3.4.3.1. New drugs in pipeline
3.4.4. Impact Analysis
3.5. Recession impact analysis for Asia-Pacific anti-inflammatory therapeutics market
CHAPTER 4: ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Biologics
4.2.1. Key market trends and growth factors
4.2.2. Market share analysis, by country
4.3. NSAIDs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market share analysis, by country
4.4. Corticosteroids
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market share analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market share analysis, by country
CHAPTER 5: ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Arthritis
5.2.1. Market share analysis, by country
5.3. Respiratory Diseases
5.3.1. Market share analysis, by country
5.4. Multiple Sclerosis
5.4.1. Market share analysis, by country
5.5. Inflammatory Bowel Disease
5.5.1. Market share analysis, by country
5.6. Psoriasis
5.6.1. Market share analysis, by country
5.7. Others
5.7.1. Market share analysis, by country
CHAPTER 6: ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Market share analysis, by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Market share analysis, by country
6.4. Online Pharmacies
6.4.1. Market share analysis, by country
CHAPTER 7: ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY COUNTRY
7.1. Overview
7.2. Asia-Pacific
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by drug class
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by distribution channel
7.2.5. Asia-Pacific market size and forecast, by country
7.2.5.1. Japan
7.2.5.1.1. Market size and forecast, by drug class
7.2.5.1.2. Market size and forecast, by indication
7.2.5.1.3. Market size and forecast, by distribution channel
7.2.5.2. China
7.2.5.2.1. Market size and forecast, by drug class
7.2.5.2.2. Market size and forecast, by indication
7.2.5.2.3. Market size and forecast, by distribution channel
7.2.5.3. Australia
7.2.5.3.1. Market size and forecast, by drug class
7.2.5.3.2. Market size and forecast, by indication
7.2.5.3.3. Market size and forecast, by distribution channel
7.2.5.4. India
7.2.5.4.1. Market size and forecast, by drug class
7.2.5.4.2. Market size and forecast, by indication
7.2.5.4.3. Market size and forecast, by distribution channel
7.2.5.5. South Korea
7.2.5.5.1. Market size and forecast, by drug class
7.2.5.5.2. Market size and forecast, by indication
7.2.5.5.3. Market size and forecast, by distribution channel
7.2.5.6. Rest of Asia-Pacific
7.2.5.6.1. Market size and forecast, by drug class
7.2.5.6.2. Market size and forecast, by indication
7.2.5.6.3. Market size and forecast, by distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.2.1. Top winning strategies, by year, 2021-2023*
8.2.2. Top winning strategies, by development, 2021-2023*(%)
8.2.3. Top winning strategies, by company, 2021-2023*
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning
CHAPTER 9: COMPANY PROFILES
9.1. ABBVIE INC.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business Performance
9.1.7. Key strategic moves and developments
9.2. AMGEN INC.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business Performance
9.3. PFIZER INC.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business Performance
9.3.7. Key strategic moves and developments
9.4. ELI LILLY AND COMPANY.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segment
9.4.5. Product portfolio
9.4.6. Business Performance
9.5. NOVARTIS AG
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business Performance
9.6. F. HOFFMANN-LA ROCHE LTD.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business Performance
9.7. JOHNSON & JOHNSON
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business Performance
9.8. GLAXOSMITHKLINE PLC
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business Performance
9.9. ASTRAZENECA PLC
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segment
9.9.5. Product portfolio
9.9.6. Business Performance
9.9.7. Key strategic moves and developments
9.10. BAYER AG
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business Performance
LIST OF TABLES
TABLE 01. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 03. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 05. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 06. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 07. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 08. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 09. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 10. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 12. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 13. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 14. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 15. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 16. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 18. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 19. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 21. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 22. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 24. REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 25. REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. ABBVIE INC.: KEY EXECUTIVES
TABLE 27. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 28. ABBVIE INC. PRODUCT SEGMENT
TABLE 29. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 30. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 31. AMGEN INC.: KEY EXECUTIVES
TABLE 32. AMGEN INC.: COMPANY SNAPSHOT
TABLE 33. AMGEN INC. PRODUCT SEGMENTS
TABLE 34. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 35. PFIZER INC.: KEY EXECUTIVES
TABLE 36. PFIZER INC.: COMPANY SNAPSHOT
TABLE 37. PFIZER INC. PRODUCT SEGMENTS
TABLE 38. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 39. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 40. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 41. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 42. ELI LILLY AND COMPANY. PRODUCT SEGMENT
TABLE 43. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 44. NOVARTIS AG: KEY EXECUTIVES
TABLE 45. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 46. NOVARTIS AG PRODUCT SEGMENTS
TABLE 47. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 48. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 49. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 50. F. HOFFMANN-LA ROCHE LTD. PRODUCT SEGMENTS
TABLE 51. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 52. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 53. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 54. JOHNSON & JOHNSON PRODUCT SEGMENTS
TABLE 55. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 56. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 57. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 58. GLAXOSMITHKLINE PLC PRODUCT SEGMENTS
TABLE 59. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 60. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 61. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 62. ASTRAZENECA PLC PRODUCT SEGMENT
TABLE 63. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 64. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 65. BAYER AG: KEY EXECUTIVES
TABLE 66. BAYER AG: COMPANY SNAPSHOT
TABLE 67. BAYER AG PRODUCT SEGMENTS
TABLE 68. BAYER AG: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIGURE 02. SEGMENTATION OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIGURE 03. TOP INVESTMENT POCKETS IN ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2023 TO 2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTION
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE COMPETITIVE RIVALRY
FIGURE 09. OPPORTUNITY, RESTRAINT, AND DRIVERS: ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIGURE 10. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR BIOLOGICS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR NSAIDS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 15. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2022-2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR ARTHRITIS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASES, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR PSORIASIS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 22. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2022 AND 2032 (%)
FIGURE 26. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2022-2032(%)
FIGURE 27. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 37. COMPETITIVE DASHBOARD
FIGURE 38. COMPETITIVE HEATMAP: METASTATIC CANCER DRUGS MARKET
FIGURE 39. TOP PLAYER POSITIONING, 2022
FIGURE 40. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 41. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 42. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 43. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 44. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 45. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 46. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 47. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 50. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. BAYER AG: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 63. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)